Alpha-1 Antitrypsin Deficiency - Epidemiology Forecast - 2032

This ‘Alpha-1 Antitrypsin Deficiency (AATD) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of alpha-1 antitrypsin deficiency, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Alpha-1 Antitrypsin Deficiency Understanding

Alpha-1 Antitrypsin Deficiency (AATD) is an inherited autosomal codominant genetic disorder characterized by a deficiency of the alpha-1 antitrypsin protein (AAT) that is essential for protecting the lungs and liver from damage caused by enzymes, and its deficiency can lead to serious respiratory and liver-related complications. It is primarily caused by mutations in the SERPINA1 gene that provides instructions for making AAT protein, which protects the body from a powerful enzyme called neutrophil elastase. The most common allele of the SERPINA1 gene, M, produces normal levels of alpha-1 antitrypsin and is present in 85-90% of individuals. Other versions of the SERPINA1 gene lead to reduced levels of AAT. The most prevalent deficiency alleles are S and Z. For example, the S allele produces moderately low levels of this protein, and the Z allele produces very little AAT. Individuals with two copies of the Z allele (ZZ) in each cell will likely have alpha-1 antitrypsin deficiency and are at high risk of developing lung disease and liver disease associated with alpha-1 antitrypsin deficiency. The Z allele is present in almost 90% of severe alpha-1 antitrypsin deficiency cases.

The onset and severity of alpha-1 antitrypsin deficiency symptoms can vary widely among individuals, even those with the same genetic mutations. Some individuals may remain asymptomatic, while others experience significant health challenges. Furthermore, individuals with alpha-1 antitrypsin deficiency are at an increased risk of developing lung conditions such as emphysema and chronic obstructive pulmonary disease (COPD). Symptoms include shortness of breath, chronic cough, wheezing, and reduced exercise tolerance.

Alpha-1 Antitrypsin Deficiency Diagnosis

An early diagnosis of alpha-1 antitrypsin deficiency is essential for preventing disease progression, timely intervention, and optimizing treatment management. Diagnosis typically involves blood tests measuring AAT levels, liver function tests, liver biopsy pulmonary function tests, imaging studies (chest X-rays or CT scans), and genetic testing identifying specific mutations.

Alpha-1 Antitrypsin Deficiency is often missed or delayed diagnosed as COPD, emphysema, chronic bronchitis, or AAT-associated liver disease as they share common respiratory and hepatitis symptoms. Thus, differential diagnosis may identify specific markers in the blood or other biological samples associated with alpha-1 antitrypsin deficiency.

Alpha-1 Antitrypsin Deficiency Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of alpha-1 antitrypsin deficiency, genotype-specific prevalent cases of alpha-1 antitrypsin deficiency, and comorbidity-associated prevalent cases of alpha-1 antitrypsin deficiency in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Alpha-1 Antitrypsin Deficiency Detailed Epidemiology Segmentation

• In 2022, there were approximately 220,352 prevalent cases of alpha-1 antitrypsin deficiency in the 7MM. The US accounted for nearly 60% of the total prevalent cases of alpha-1 antitrypsin deficiency in the 7MM, and these cases are expected to increase during the forecast period.
• As per The epidemiology model, the genotype of alpha-1 antitrypsin deficiency was divided into three groups: PiZZ, PiSZ, and others (including PiMZ and other less common genotypes). In 2022, there were approximately 119,274, 7,316, and 5,937 cases of PiZZ, PiSZ, and other genotypes, respectively. The genotype-specific prevalent cases of alpha-1 antitrypsin deficiency are projected to increase by 2032.
• In 2022, in the US, comorbidity associated with lung diseases was most common, occurring in around 77% of the total alpha-1 antitrypsin deficiency cases, followed by other diseases occurring in around 15% of the cases, while 8% of the cases had liver diseases. The report estimates that by 2032, these cases are expected to increase.
• Among EU4 and the UK, the UK accounted for the highest diagnosed prevalent cases of alpha-1 antitrypsin deficiency, around 22,597 cases, while Italy had the least cases of alpha-1 antitrypsin deficiency, nearly 12,219 in 2022.
• In EU4 and the UK, of the total prevalent cases of alpha-1 antitrypsin deficiency, around 78% were PiZZ genotypes, 10% were PiSZ, and nearly 12% were of other genotypes in 2022. These cases are expected to rise during the forecast period (2023-2032).
• In EU4 and the UK, comorbidities associated with lung diseases were ranked first with 70,546 cases, followed by other diseases with 8,939 cases, and liver disease with 8,316 cases in 2022.
• In 2022, Japan accounted for the lowest prevalent cases of alpha-1 antitrypsin deficiency among the 7MM, making up nearly 0.01% of the total cases. The cases are estimated to change during the forecast period.
• In Japan, lung disease-associated comorbidities in alpha-1 antitrypsin deficiency occurred in around 18 cases, while liver diseases and other diseases were found in nearly two and three cases of alpha-1 antitrypsin deficiency, respectively, in 2022.

Scope of the Report

• The report covers a descriptive overview of alpha-1 antitrypsin deficiency, explaining its symptoms, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of alpha-1 antitrypsin deficiency.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, the total prevalent cases of alpha-1 antitrypsin deficiency, genotype-specific prevalent cases of alpha-1 antitrypsin deficiency, and comorbidity-associated prevalent cases of alpha-1 antitrypsin deficiency.

Report Highlights

• Ten Years Forecast of Alpha-1 Antitrypsin Deficiency
• The 7MM Coverage
• Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency
• Gender-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency
• Comorbidity-associated Prevalent Cases of Alpha-1 Antitrypsin Deficiency

Key Questions Answered

• What are the disease risks and burdens of alpha-1 antitrypsin deficiency?
• What is the historical alpha-1 antitrypsin deficiency patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of alpha-1 antitrypsin deficiency at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with alpha-1 antitrypsin deficiency?
• Which country would have the highest diagnosed prevalent population of alpha-1 antitrypsin deficiency among the countries mentioned above during the forecast period (2023-2032)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy

The Alpha-1 Antitrypsin Deficiency report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM alpha-1 antitrypsin deficiency epidemiology forecast.
• The alpha-1 antitrypsin deficiency epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The alpha-1 antitrypsin deficiency epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by Segmentation
• Factors Driving Growth in a Specific Patient Population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032